Effects of Tualang honey on quality of life and biochemical markers in breast cancer patients treated with anastrozole

Effects of Tualang honey on quality of life and biochemical markers in breast cancer patients treated with anastrozole: an open-label randomized controlled trial study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN89213965

Enrollment

Registered

2016-09-18

Start date

2014-09-23

Completion date

Unknown

Last updated

2016-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer in postmenopausal women Cancer Breast cancer

Interventions

Eighty-four postmenopausal breast cancer patients from Oncology Clinic, Universiti Sains Malaysia Hospital with stages I, II, and III, and treated with anastrozole (1 mg/day) are randomly assigned int

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal women treated with anastrozole and with breast cancer stages I, II and III estrogen receptor (ER+) positive and/or progesterone receptor (PR+) positive.

Exclusion criteria

Exclusion criteria: Any subject that has history of allergy to honey, severe infection, and/or receiving hormone and/or replacement therapy are excluded from this study.

Design outcomes

Primary

Measure	Time frame
1. Quality of life status by using Quality of Life Questionnaire-Core 36 (EQRTC-QLQ-C30) 2. Blood oxidative stress status by assessing the levels of malonaldehyde, total antioxidant status, protein carbonyl, reduced glutathione (GSH): oxidised glutathione (GSSG) ratio, erythrocyte superoxide dismutase, catalase, glutathione peroxidase using commercial kits 3. Blood breast cancer markers which include carcinoembryonic antigen and CA15-3 using commercial kits All these outcomes are measured at baseline (Visit 1) and after 3 months (Visit 2)	—

Measure

Time frame

1. Quality of life status by using Quality of Life Questionnaire-Core 36 (EQRTC-QLQ-C30) 2. Blood oxidative stress status by assessing the levels of malonaldehyde, total antioxidant status, protein carbonyl, reduced glutathione (GSH): oxidised glutathione (GSSG) ratio, erythrocyte superoxide dismutase, catalase, glutathione peroxidase using commercial kits 3. Blood breast cancer markers which include carcinoembryonic antigen and CA15-3 using commercial kits All these outcomes are measured at baseline (Visit 1) and after 3 months (Visit 2)

—

Secondary

Measure	Time frame
1. Safety profile which include full blood count, fasting blood glucose, liver function test and renal function test 2. Blood inflammatory markers which include high-sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin 1ß (IL-1ß) and tumour necrosis factor- a (TNF- a) using commercial kits 3. Blood bone markers which include C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N propeptide (P1NP) using commercial kits 4. Blood estradiol using commercial kits All these outcomes are measured at baseline (Visit 1) and after 3 months (Visit 2)	—

Measure

Time frame

1. Safety profile which include full blood count, fasting blood glucose, liver function test and renal function test 2. Blood inflammatory markers which include high-sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), interleukin 1ß (IL-1ß) and tumour necrosis factor- a (TNF- a) using commercial kits 3. Blood bone markers which include C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N propeptide (P1NP) using commercial kits 4. Blood estradiol using commercial kits All these outcomes are measured at baseline (Visit 1) and after 3 months (Visit 2)

—

Countries

Malaysia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026